Ilapro D Capsule PR is a combination pharmaceutical formulation containing Domperidone 30 mg and Ilaprazole 10 mg, designed for the management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and gastroparesis. Ilaprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The combination of these two agents offers a synergistic therapeutic approach by simultaneously enhancing gastric motility and reducing acid secretion, which is beneficial in patients presenting with dyspeptic symptoms accompanied by acid reflux. Ilapro D Capsule PR is typically administered orally, with dosing tailored according to clinical response and physician discretion. It is contraindicated in patients with known hypersensitivity to either component, significant hepatic impairment, or prolactinoma. Caution is advised in patients with cardiac arrhythmias or electrolyte imbalances due to Domperidone’s potential to prolong the QT interval. This combination therapy should be used under medical supervision to optimize efficacy and minimize adverse effects.